Coegin Pharma

Executive Summary

Coegin Pharma is a Swedish biotech company focused on innovative peptide-based solutions for hair and skin health. The company is currently commercializing its patented hair density innovation, Follicopeptide®, on a global scale, targeting the large and growing hair loss treatment market. Follicopeptide is a cosmetic active ingredient that aims to improve hair density and thickness, positioned as a natural alternative to pharmaceutical treatments like minoxidil. Additionally, Coegin is developing a next-generation peptide, NPP-4, which represents a novel biotechnological approach to enhancing skin tone and addressing pigmentation disorders. The company leverages advanced peptide discovery and formulation expertise to create differentiated products for dermatology and aesthetic medicine. While Follicopeptide provides near-term revenue potential through licensing and distribution partnerships, NPP-4 is at an earlier stage of development, likely in preclinical or early clinical phases. Coegin operates in the competitive landscape of cosmeceuticals and dermatological therapeutics, with a focus on evidence-based efficacy and regulatory compliance. The company's strategy involves securing partnerships for manufacturing, marketing, and distribution to maximize global reach. As a private company, Coegin's financial details are limited, but its dual pipeline of commercialized and development-stage assets positions it for potential growth if clinical and commercial milestones are met. The main risks include regulatory hurdles for NPP-4 and market adoption of Follicopeptide amidst established competitors.

Upcoming Catalysts (preview)

• TBDFollicopeptide Global Commercialization Milestones70% success
• Q3 2026NPP-4 Clinical Trial Initiation or Early Data40% success
• TBDStrategic Partnership or Licensing Agreement for Follicopeptide60% success